Loading candles…
Sun Pharma Advanced Research Company Ltd, incorporated in 2007 as a spin-off from Sun Pharmaceutical Industries Ltd, operates as an independent research entity within the pharmaceutical and biopharmaceutical industries. The company specializes in the research and development of pharmaceutical products, focusing on novel therapies that include the discovery and development of new chemical entities (NCEs) and reformulated products tailored for global markets. Its primary therapeutic areas encompass oncology, immunology, and neurology.
This page is a live market overview for SUN PHARMA ADV.RES.CO.LTD (SPARC) on the NSE. As a listed security, SUN PHARMA ADV.RES.CO.LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SPARC before placing trades on tick2trade.
As of the latest feed, SPARC last traded at ₹213.21 on NSE, down ₹3.77 (1.74%) from the previous close of ₹216.98. Today's session range is ₹211 – ₹217.03, against a 52-week band of ₹108 – ₹289. Traded volume today stands at 6.07L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SPARC in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SPARC is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SUN PHARMA ADV.RES.CO.LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SPARC. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SPARC option chain page linked from this overview.
| Date |
|---|
| Unaudited Results - Q1-FY26 | To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 | 10 Aug 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026 | 18 May 2026 |
| Unaudited Results - Q3-FY25 | To consider and approve the Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025 | 9 Feb 2026 |
| Fund Raising | To consider Fund Raising through Preferential Allotment | 14 Jan 2026 |
| Unaudited Results - Q2 & FY25 | Sun Pharma Advanced Research Company Limited has informed the exchange about Board Meeting to be held on 10-Nov-2025 to inter-alia consider and approve the U… | 10 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 4 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 19 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.